Patents by Inventor Maj HEDTJÄRN

Maj HEDTJÄRN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220146496
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: January 21, 2022
    Publication date: May 12, 2022
    Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Patent number: 11320421
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: May 3, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Publication number: 20220025376
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 27, 2022
    Inventors: Nanna ALBÆK, Maj HEDTJÄRN, Marie Wickstrom LINDHOLM, Niels Fisker NIELSEN, Andreas PETRI, Jacob RAVN
  • Patent number: 11091764
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: August 17, 2021
    Assignee: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Nanna Albæk, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Publication number: 20200348286
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: July 20, 2020
    Publication date: November 5, 2020
    Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Patent number: 10739332
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: August 11, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Publication number: 20200248186
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: September 4, 2019
    Publication date: August 6, 2020
    Inventors: Nanna ALBÆK, Maj HEDTJÄRN, Marie Wickstrom LINDHOLM, Niels Fisker NIELSEN, Andreas PETRI, Jacob RAVN
  • Patent number: 10718753
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: July 21, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Publication number: 20200057052
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: October 24, 2019
    Publication date: February 20, 2020
    Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Patent number: 10494633
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: December 3, 2019
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Patent number: 10443058
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: October 15, 2019
    Assignee: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Nanna Albæk, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Publication number: 20190310244
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: April 18, 2019
    Publication date: October 10, 2019
    Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Patent number: 10385342
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: August 20, 2019
    Assignee: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Nanna Albæk, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Patent number: 10370668
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: August 6, 2019
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Nanna Albæk, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Publication number: 20180312847
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: May 4, 2018
    Publication date: November 1, 2018
    Inventors: Nanna ALBÆK, Maj HEDTJÄRN, Marie Wickstrom LINDHOLM, Niels Fisker NIELSEN, Andreas PETRI, Jacob RAVN
  • Publication number: 20180312846
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: May 4, 2018
    Publication date: November 1, 2018
    Inventors: Nanna ALBÆK, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Publication number: 20180216116
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: December 8, 2017
    Publication date: August 2, 2018
    Inventors: Nanna Albaek, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Patent number: 9879265
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: January 30, 2018
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Nanna Albæk, Maj Hedtjärn, Marie Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Publication number: 20170191064
    Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
    Type: Application
    Filed: November 14, 2016
    Publication date: July 6, 2017
    Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
  • Publication number: 20160138025
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Application
    Filed: June 27, 2014
    Publication date: May 19, 2016
    Inventors: Nanna ALBÆK, Maj HEDTJÄRN, Marie LINDHOLM, Niels Fisker NIELSEN, Andreas PETRI, Jacob RAVN